Nanoscope Therapeutics successfully treated 11 patients blinded by advanced retinitis pigmentosa (RP). A single intravitreal injection produced positive results that persisted through one year. The startup plans a Phase 2b trial this summer and plans to develop gene therapies to treat more common retinal diseases—like dry age-related macular degeneration.